{
    "id": "a6b9dba8-fc5a-4a57-b43e-d7614df1b8bd",
    "indications": {
        "text": "blisovi fe 1/20 indicated prevention pregnancy women elect oral contraceptives method contraception . oral contraceptives highly effective . table lists typical accidental pregnancy rates users combination oral contraceptives methods contraception . efficacy contraceptive methods , except sterilization , depends upon reliability used . correct consistent methods result lower failure rates . table : lowest expected typical failure rates first year continuous method adapted rheumatoid arthritis hatcher et al , reference 7 . % women experiencing unintended pregnancy first year continuous method lowest expectedthe authors ' best guess percentage women expected experience accidental pregnancy among couples initiate method ( necessarily first time ) consistently correctly first year stop reason . typicalthis term represents `` typical `` couples initiate method ( necessarily first time ) , experience accidental pregnancy first year stop reason . ( contraception ) ( 85 ) ( 85 ) oral contraceptives 3 combined 0.1 n/an/a-data available progestin 0.5 n/a diaphragm spermicidal cream jelly 6 20 spermicides alone ( foam , creams , gels , vaginal suppositories , vaginal film ) 6 26 vaginal sponge nulliparous 9 20 parous 20 40 implant 0.05 0.05 injection : depot medroxyprogesterone acetate 0.3 0.3 iud progesterone 1.5 2.0 copper 380a 0.6 0.8 lng 20 0.1 0.1 condom without spermicides female 5 21 male 3 14 cervical cap spermicidal cream jelly nulliparous 9 20 parous 26 40 periodic abstinence ( methods ) 1 9 25 withdrawal 4 19 female sterilization 0.5 0.5 male sterilization 0.10 0.15",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "blister designed make oral contraceptive dosing easy convenient possible . tablets arranged four rows seven tablets , days week appearing blister first row tablets . note : blister preprinted days week , starting sunday , facilitate sunday-start regimen . six different day label strips provided detailed patient & brief summary patient package insert order accommodate day-1 start regimen . patient using day-1 start regimen , place self-adhesive day label strip corresponds starting day preprinted days . important : patient instructed additional method protection first week initial cycle utilizing sunday-start regimen . possibility ovulation conception prior initiation considered .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "blisovi fe 1/20 ( norethindrone acetate ethinyl estradiol tablets usp , 1 mg/0.02 mg ; ferrous fumarate tablets ) available blister ( ndc 68180-865-71 ) containing 28 tablets packed pouch ( ndc 68180-865-71 ) . three pouches packaged carton ( ndc 68180-865-73 ) . blister contains 28 tablets , follows : 21 yellow coloured , round flat face beveled edged tablets , containing 1 mg norethindrone acetate 0.02 mg ethinyl estradiol , debossed `` lu `` one side `` j23 `` side . 7 brown mottled , round , flat face beveled edged tablets debossed `` lu `` one side `` m22 `` side . brown tablet contains 75 mg ferrous fumarate . ferrous fumarate tablets present facilitate ease via 28-day regimen , non-hormonal , serve therapeutic purpose . store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15 30\u00b0c ( 59 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "oral contraceptives contraindicated women currently following conditions : thrombophlebitis thromboembolic disorders past history deep vein thrombophlebitis thromboembolic disorders cerebral vascular coronary artery disease current diagnosis , history , breast cancer , may hormone sensitive carcinoma endometrium known suspected estrogen-dependent neoplasia undiagnosed abnormal genital bleeding cholestatic jaundice pregnancy jaundice prior pill hepatic adenomas carcinomas receiving hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir , due potential alt elevations ( , risk liver enzyme elevations concomitant hepatitis c treatment ) .",
    "ingredients": [],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "Blisovi Fe 1/20",
    "effectiveTime": "20250515",
    "indications_original": "Blisovi Fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.\n                  Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.\n                  \n                     TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD\n                  \n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              Adapted from RA Hatcher et al, Reference 7.\n                           \n                        \n                     \n                     \n                        \n                           \n                               %\n                               of\n                               Women\n                               Experiencing\n                               an\n                               Unintended\n                               Pregnancy\n                               in\n                               the\n                               First\n                               Year\n                               of\n                               Continuous\n                               Use\n                              \n                           \n                        \n                        \n                           \n                               Method\n                              \n                           \n                           \n                               Lowest\n                               ExpectedThe authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.\n                              \n                              \n                           \n                           \n                               TypicalThis term represents \"typical\" couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.\n                              \n                              \n                           \n                        \n                        \n                            (No contraception)\n                           \n                            (85)\n                           \n                            (85)\n                           \n                        \n                        \n                            Oral contraceptives\n                           \n                           \n                            3\n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Combined\n                           \n                            0.1\n                           \n                            N/AN/A--Data not available\n                              \n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Progestin only\n                           \n                            0.5\n                           \n                            N/A\n                              \n                           \n                        \n                        \n                            Diaphragm with spermicidal cream or jelly\n                           \n                            6\n                           \n                            20\n                           \n                        \n                        \n                            Spermicides alone (foam, creams, gels, vaginal suppositories, and vaginal film)\n                           \n                            6\n                           \n                            26\n                           \n                        \n                        \n                            Vaginal Sponge\n                           \n                           \n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Nulliparous\n                           \n                            9\n                           \n                            20\n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Parous\n                           \n                            20\n                           \n                            40\n                           \n                        \n                        \n                            Implant\n                           \n                            0.05\n                           \n                            0.05\n                           \n                        \n                        \n                            Injection: depot medroxyprogesterone acetate\n                           \n                            0.3\n                           \n                            0.3\n                           \n                        \n                        \n                            IUD\n                           \n                           \n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Progesterone T\n                           \n                            1.5\n                           \n                            2.0\n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Copper T 380A\n                           \n                            0.6\n                           \n                            0.8\n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0LNg 20\n                           \n                            0.1\n                           \n                            0.1\n                           \n                        \n                        \n                            Condom without spermicides\n                           \n                           \n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Female\n                           \n                            5\n                           \n                            21\n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Male\n                           \n                            3\n                           \n                            14\n                           \n                        \n                        \n                            Cervical Cap with spermicidal cream of jelly\n                           \n                           \n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Nulliparous\n                           \n                            9\n                           \n                            20\n                           \n                        \n                        \n                            \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Parous\n                           \n                            26\n                           \n                            40\n                           \n                        \n                        \n                            Periodic abstinence (all methods)\n                           \n                            1 to 9\n                           \n                            25\n                           \n                        \n                        \n                            Withdrawal\n                           \n                            4\n                           \n                            19\n                           \n                        \n                        \n                            Female sterilization\n                           \n                            0.5\n                           \n                            0.5\n                           \n                        \n                        \n                            Male sterilization\n                           \n                            0.10\n                           \n                            0.15",
    "contraindications_original": "The blister has been designed to make oral contraceptive dosing as easy and as convenient as possible. The tablets are arranged in four rows of seven tablets each, with the days of the week appearing on the blister above the first row of tablets.\n                  \n                     Note: Each blister has been preprinted with the days of the week, starting with Sunday, to facilitate a Sunday-Start regimen. Six different day label strips have been provided with the Detailed Patient & Brief Summary Patient Package Insert in order to accommodate a Day-1 Start regimen. If the patient is using the Day-1 Start regimen, she should place the self-adhesive day label strip that corresponds to her starting day over the preprinted days.\n                  \n                     Important: The patient should be instructed to use an additional method of protection until after the first week of administration in the initial cycle when utilizing the Sunday-Start regimen.\n                  The possibility of ovulation and conception prior to initiation of use should be considered.",
    "warningsAndPrecautions_original": "Blisovi\u00a0Fe\u00a01/20\u00a0(norethindrone acetate and ethinyl estradiol tablets USP, 1 mg/0.02 mg; and ferrous fumarate tablets) are available in a blister (NDC 68180-865-71) containing 28 tablets packed in a pouch (NDC 68180-865-71). Such three pouches are packaged in a carton (NDC 68180-865-73).\n                  Each blister contains 28 tablets, as follows:\n                  \n                     21 yellow coloured, round flat face beveled edged tablets, each containing 1 mg      norethindrone acetate and 0.02 mg ethinyl estradiol, debossed with \"LU\"      on one side and \"J23\" on the other side.\n                     7 brown mottled, round, flat face beveled edged tablets      debossed with \"LU\" on one side and \"M22\" on the other side.      Each brown tablet contains 75 mg ferrous fumarate. The ferrous fumarate      tablets are present to facilitate ease of drug administration via a 28-day      regimen, are non-hormonal, and do not serve any therapeutic purpose.\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15 to 30\u00b0C (59 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Oral contraceptives are contraindicated in women who currently have the following conditions:\n                  \n                     Thrombophlebitis or thromboembolic disorders\n                     A past history of deep vein thrombophlebitis or thromboembolic disorders\n                     Cerebral vascular or coronary artery disease\n                     Current diagnosis of, or history of, breast cancer, which may be hormone sensitive\n                     Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia\n                     Undiagnosed abnormal genital bleeding\n                     Cholestatic jaundice of pregnancy or jaundice with prior pill use\n                     Hepatic adenomas or carcinomas\n                     Are receiving Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations (see WARNINGS, RISK OF LIVER ENZYME ELEVATIONS WITH CONCOMITANT HEPATITIS C TREATMENT).",
    "drug": [
        {
            "name": "Blisovi Fe 1/20"
        }
    ]
}